The Tartu-based medtech startup Menken Trials, aiming to spare doctors of paperwork, has raised a €1.3 million grant from EAS and Kredex. The fresh costs will support the startup’s growth plans.
- Founded in 2021, Menken develops an AI to automate and improve the monitoring of clinical trials. The startup claims it makes them faster, more accurate, and efficient. By automating monitoring in clinical trials with real-time compliance checks and error detection, its solutions aim to fill a critical gap in the market.
We believe that our success comes from changing the way clinical trial operations are viewed and carried out. By focusing on improving workflows, we aim to make clinical trials more efficient and compliant, — Anna-Liisa Parts, one of the co-founders, commented.
- Recently, Menken Trials has entered Tenity, a Swiss-backed early-stage investing and accelerating program now operating in Estonia, as part of their growth efforts. The startup added that this partnership will help us expand in Central Europe, reaching more hospitals and biopharmas over the next 12 months.
- The grant was provided by the Tallinn-based EASi ja KredExi ühendasutus, the joint organisation, supporting entrepreneurship and the improvement of living conditions in Estonia, increase its international competitiveness, visibility and attractiveness as a place for business, living and studies. Estonian Business and Innovation Agency projects are co-funded from the European Regional Development Fund.
The fresh grant will help the startup to expand into Eastern Europe and Africa and to support its mission to improve clinical trial processes worldwide.
